Kiessling H.,University of Tubingen |
Schulz I.,Microfluidic ChipShop GmbH |
Haltner E.,Across Barriers GmbH |
Fricker G.,University of Heidelberg |
And 2 more authors.
BioSpektrum | Year: 2015
State of the art animal and cell culture models fail to predict the ability of drugs to cross the blood-brain barrier as they lack comparability to the complex human situation. The development of novel pharmaceutics therefore requires in vitro models with human like cell response. Therefore, we are developing a model which mimics the organ environment including the specific 3D arrangement of different cell types, extracellular matrix, and perfusion by combining biology, biochemistry and microfluidic technology. © 2015, Springer-Verlag Berlin Heidelberg.
Eixarch H.,Across Barriers GmbH |
Haltner-Ukomadu E.,Across Barriers GmbH |
Beisswenger C.,Across Barriers GmbH |
Bock U.,Across Barriers GmbH
Journal of Epithelial Biology and Pharmacology | Year: 2010
The respiratory tract is currently considered as an alternative to gastrointestinal and dermal drug delivery systems and is used to deliver drugs for respiratory diseases as well as the treatment of non-pulmonary disorders. The first step in drug profiling for delivery via the respiratory tract needs to address intrinsic physicochemical parameters and their impact on or correlation with absorption. Moreover, the more the pulmonary drug delivery shall find acceptance, the greater will be the need for validated test systems, methods, and guidelines for regulatory purposes. The Biopharmaceutical Classification System (BCS) remains the simplest and most common guiding principle for predicting drug absorption, but it is limited to the gastrointestinal tract. This review suggests an extension, the pulmonary Biopharmaceutical Classification System (pBCS), that will take into consideration the specific biology of the lung as well as particle deposition, aerosol physics, and the subsequent processes of drug absorption and solubility. We will describe the steps to be taken to develop a pBCS as well as the compounds that will be used to establish this classification. Furthermore, we will introduce two cellular models with which drug permeability across the pulmonary barrier will be determined as an alternative to the currently and widely used studies with animals. © Eixarch et al.